Taysha Gene Therapies (NASDAQ:TSHA) Sees Strong Trading Volume


Share on StockTwits

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) saw an uptick in trading volume on Tuesday . 7,586 shares traded hands during mid-day trading, a decline of 91% from the previous session’s volume of 86,015 shares.The stock last traded at $22.78 and had previously closed at $23.57.

A number of equities analysts have weighed in on TSHA shares. Oppenheimer began coverage on shares of Taysha Gene Therapies in a report on Monday, January 4th. They issued an “outperform” rating and a $42.00 price target on the stock. William Blair began coverage on shares of Taysha Gene Therapies in a report on Monday, March 1st. They set an “outperform” rating and a $46.00 target price on the stock. Zacks Investment Research lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, March 9th. Chardan Capital reaffirmed a “buy” rating on shares of Taysha Gene Therapies in a research note on Monday, April 26th. Finally, Morgan Stanley lifted their price target on shares of Taysha Gene Therapies from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, April 19th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $43.92.

The company has a fifty day moving average of $22.89 and a 200 day moving average of $24.44.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, March 2nd. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.68). Equities analysts expect that Taysha Gene Therapies, Inc. will post -3.19 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Citigroup Inc. purchased a new stake in Taysha Gene Therapies in the 4th quarter valued at $43,000. Strs Ohio purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $55,000. New York State Common Retirement Fund purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $130,000. American International Group Inc. purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $134,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $330,000. 42.19% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile (NASDAQ:TSHA)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.

Featured Story: What economic reports are most valuable to investors?

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.